ArticleBJUI compass2026
Salvage prostate therapies for local pelvic recurrence after primary radiation for prostate cancer.
Article in BJUI compass, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Salvage prostate therapies for local pelvic recurrence after primary radiation for prostate cancer.BJUI compass · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: The purpose of this study is to evaluate salvage treatment after primary radiation therapy (RT) for prostate cancer within our hospital system. Specifically, we aim to evaluate treatment patterns, oncologic outcomes and complications. Materials and methods: We retrospectively identified men with post-RT recurrence treated with salvage radical prostatectomy (sRP), seminal vesiculectomy, cryoablation, high-dose-rate brachytherapy (HDR) or irreversible electroporation (IRE). Salvage failure was defined as biochemical recurrence (BCR; Phoenix criteria, nadir + 2 ng/mL for cryoablation, HDR and IRE or prostate-specific antigen (PSA) > 0.2 ng/mL for sRP and seminal vesiculectomy) or need for subsequent therapy. Cox regression identified factors associated with time to failure. Results: Seventy-one patients underwent salvage therapy after RT; 58 (81.7%) cryoablation, 7 (9.9%) sRP, 2 (2.8%) robotic seminal vesiculectomies, and 4 (5.6%) other modalities. Failure occurred in 30 (45%) patients at a median of 12.5 months (IQR 6, 23). Grade group (GG) 4-5 disease prior to RT was associated with time to failure (HR 2.18, 95% CI 0.96, 4.97, Conclusions: In this institutional cohort, salvage cryoablation demonstrated an acceptable short-term failure-free survival with fewer observed high-grade complications than salvage prostatectomy. Salvage cryoablation also appeared feasible in select patients with low-volume nodal or metastatic disease. These findings are hypothesis-generating and require prospective validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.